Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the FDA adverse event reporting system.

@article{Wu2022AnalysisOA,
  title={Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the FDA adverse event reporting system.},
  author={Bin Wu and Pengfei Shen and Xianya Yin and Lei Yu and Fengbo Wu and Chen Chen and Jian Li and Ting Xu},
  journal={British journal of clinical pharmacology},
  year={2022}
}
  • Bin Wu, P. Shen, Ting Xu
  • Published 29 March 2022
  • Medicine, Biology
  • British journal of clinical pharmacology
AIM To investigate interstitial lung disease (ILD) in men with prostate cancer receiving hormone therapy. METHODS We gathered cases diagnosed with prostate cancer based on the United States food and drug administration adverse event reporting system (FAERS) database from 2004 to 2020. We divided the included cases into three groups based on the primary suspected drugs: a hormone therapy group, a positive control group (taxanes), and a negative control group. We employed reporting odds ratio…